Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate - Xenikos

Drug Profile

Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate - Xenikos

Alternative Names: HENO 3; MabCD3-dgA/CD7-dgA; T-Guard

Latest Information Update: 13 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Radboud-University-Nijmegen-Medical-Centre
  • Developer Xenikos
  • Class Drug conjugates; Immunotoxins; Lectins; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Protein synthesis inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes - Graft-versus-host disease

Highest Development Phases

  • Phase I/II Graft-versus-host disease

Most Recent Events

  • 13 Mar 2019 Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate is still in phase II trials for Graft-versus-host disease in Germany and Netherlands (Xenikos website, March 2019)
  • 27 Dec 2018 Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate is available for licensing as of 27 Dec 2018 (Xenikos pipeline, December 2018)
  • 20 Dec 2018 Xenikos announces intention to file an IND application with the US FDA for for Graft-versus-host disease in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top